

October 2, 2012

Pharmacy Announcement

Preferred Drug List (PDL) Changes Effective September 24, 2012

On June 27, 2012, the Pharmacy and Therapeutics (P&T) Committee of the Nevada Department of Health and Human Services' Division of Health Care Financing and Policy met to review new and existing therapeutic drug classes on the Nevada Medicaid Preferred Drug List (PDL).

The actions taken by the committee are indicated below. All changes are effective September 24, 2012. The complete PDL is posted on the "[Preferred Drug List](#)" webpage.

Drug Class	Drugs Added	Drugs Removed	Drugs Reviewed But Not Added
Androgenic Agents: Topical	None	None	Fortesta®
Anticonvulsants – Benzodiazepines	None	None	Onfi®
Diabetic Agents: DPP-4 Inhibitors and Combinations	Janumet XR®, Jentaduetto®, Juvisync®	None	None
Neuropathic Pain Agents (<i>new</i>)	Cymbalta®, Gabapentin, Lyrica®	None	Gralise®, Lidoderm®, Horizant®
Ophthalmic Glaucoma Agents: Prostaglandins	Zioptan®	None	None
Pediculocides/Scabicides (<i>new</i>)	Natroba®, NIX®, RID, Permethrin	None	Eurax®, Malathion, Ovide®, Ulesfia®, Lindane
Platelet Aggregation Inhibitors	Anagrelide, Brilinta®, Cilostazol®, Clopidogrel, Ticlopidine	Effient™, Plavix®(brand only)	None
Respiratory: Inhaled Corticosteroid/Beta-Adrenergic Combinations	Dulera®	None	None
Respiratory: Intranasal Steroid	None	None	QNASL®
Restless Leg Syndrome Agents (<i>new</i>)	Pramipexole, Requip XL®, Ropinirole	None	Horizant®